Buscar
Mostrando ítems 11-15 de 15
Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain
(Alimentary Pharmacology and Therapeutics, 2023)
Background: Chronic hepatitis B virus (HBV) infection is a major cause of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented in Spain two decades ago, and potent oral antivirals ...
Treatment of hepatitis delta and HIV infection
(Liver International, 2023)
Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5–10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15–25 million ...
Hot News. A cure for HIV on the horizon
(Aids Reviews, 2022)
[Resumen no disponible]
Safety considerations in the management of hepatitis C and HIV co-infection
(Expert Opinion on Drug Safety, 2023)
Introduction: Both HCV and HIV are highly prevalent infections with current estimates of 57 and 38 million people infected worldwide, respectively. Oral antivirals can be curative for HCV and rescue HIV patients from disease ...
Triple Threat: HDV, HBV, HIV Coinfection
(Clinics in Liver Disease, 2023)
First discovered in the late 1970s, hepatitis delta virus (HDV) has emerged as an important driver of decompensated liver disease and hepatocellular carcinoma (HCC) worldwide. HDV requires hepatitis B virus (HBV) for ...